NR2F1 and breast cancer: Additionally, a string of assays both in vivo and in vitro were performed to verify the role of the LINC00663/EBF1/NR2F1 axis in BC progression, and results showed that silencing LINC00663 inhibited inflammation and angiogenesis in BC partially by decreasing NR2F1 expression via binding EBF1.